Cost–Utility Analysis of a Medication Adherence Management Service Alongside a Cluster Randomized Control Trial in Community Pharmacy
Authors:
- Maria-Isabel Valverde-MerinoMaria-Isabel Valverde-Merino
- Fernando Martinez-MartinezFMFernando Martinez-Martinez
- Leticia Garcia-MochonLGLeticia Garcia-Mochon
- Shalom I BenrimojSBShalom I Benrimoj
- Amaia Malet-LarreaAMAmaia Malet-Larrea
- Beatriz Perez-EscamillaBPBeatriz Perez-Escamilla
- Maria Jose ZarzueloMZMaria Jose Zarzuelo
- Andrea Torres-RoblesATAndrea Torres-Robles
- Miguel Angel GastelurrutiaMGMiguel Angel Gastelurrutia
- Raquel Varas-DovalRVRaquel Varas-Doval
- Tamara Peiro ZorrillaTZTamara Peiro Zorrilla
- Victoria Garcia-CardenasVGVictoria Garcia-Cardenas
Open Access
- 1 October 2021
- journal article
- research article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 15, 2363-2376
Abstract
Background: It is necessary to determine the cost utility of adherence interventions in chronic diseases due to humanistic and economic burden of non-adherence. Purpose: To evaluate, alongside a cluster-randomized controlled trial, the cost-utility of a pharmacist-led medication adherence management service (MAMS) compared with usual care in community pharmacies. Materials and Methods: The trial was conducted over six months. Patients with treatments for hypertension, asthma or chronic obstructive pulmonary disease (COPD) were included. Patients in the intervention group (IG) received a MAMS based on a brief complex intervention, whilst patients in the control group (CG) received usual care. The cost–utility analysis adopted a health system perspective. Costs related to medications, healthcare resources and adherence intervention were included. The effectiveness was estimated as quality-adjusted life years (QALYs), using a multiple imputation missing data model. The incremental cost–utility ratio (ICUR) was calculated on the total sample of patients. Results: A total of 1186 patients were enrolled (IG: 633; CG: 553). The total intervention cost was estimated to be € 27.33 ± 0.43 per patient for six months. There was no statistically significant difference in total cost of medications and healthcare resources per patient between IG and CG. The values of EQ-5D-5L at 6 months were significantly higher in the IG [IG: 0.881 ± 0.005 vs CG: 0.833 ± 0.006; p = 0.000]. In the base case, the service was more expensive and more effective than usual care, resulting in an ICUR of € 1,494.82/QALY. In the complete case, the service resulted in an ICUR of € 2,086.30/QALY, positioned between the north-east and south-east quadrants of the cost–utility plane. Using a threshold value of € 20,000/QALY gained, there is a 99% probability that the intervention is cost-effective. Conclusion: The medication adherence management service resulted in an improvement in the quality of life of the population with chronic disease, with similar costs compared to usual care. The service is cost-effective.Keywords
This publication has 55 references indexed in Scilit:
- Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid ApproachMedical Care, 2017
- Interventions for enhancing medication adherenceCochrane Database of Systematic Reviews, 2014
- A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled TrialsPharmacoEconomics, 2014
- Cost of poor adherence to anti-hypertensive therapy in five European countriesThe European Journal of Health Economics, 2014
- Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: a cost-effectiveness analysisRespiratory Research, 2014
- Learning curves, taking instructions, and patient safety: using a theoretical domains framework in an interview study to investigate prescribing errors among trainee doctorsImplementation Science, 2012
- Adherence to Medications: Insights Arising from Studies on the Unreliable Link Between Prescribed and Actual Drug Dosing HistoriesAnnual Review of Pharmacology and Toxicology, 2012
- A cost-consequences analysis of an adherence focused pharmacist-led medication review serviceInternational Journal of Pharmacy Practice, 2011
- Cost-utility analysis of a pharmacy-led self-management programme for patients with COPDInternational Journal of Clinical Pharmacy, 2011
- Learning by Doing Something Else: Variation, Relatedness, and the Learning CurveManagement Science, 2003